Revance Therapeutics (NASDAQ:RVNC) will release its earnings data after the market closes on Monday, February 22nd. Analysts expect Revance Therapeutics to post earnings of ($1.16) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Shares of NASDAQ:RVNC opened at $28.97 on Monday. The firm has a fifty day moving average of $28.17 and a two-hundred day moving average of $26.68. The firm has a market capitalization of $1.93 billion, a P/E ratio of -6.30 and a beta of 1.42. Revance Therapeutics has a 12-month low of $11.78 and a 12-month high of $34.62. The company has a quick ratio of 7.01, a current ratio of 7.07 and a debt-to-equity ratio of 0.48.
In related news, insider Aubrey Rankin sold 33,119 shares of the business’s stock in a transaction dated Monday, February 1st. The stock was sold at an average price of $25.95, for a total transaction of $859,438.05. Following the completion of the transaction, the insider now owns 67,871 shares of the company’s stock, valued at approximately $1,761,252.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.80% of the company’s stock.
A number of brokerages have issued reports on RVNC. Barclays lifted their target price on shares of Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Monday, October 26th. Zacks Investment Research lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Needham & Company LLC lifted their price objective on shares of Revance Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, January 8th. Finally, Mizuho reduced their price objective on shares of Revance Therapeutics from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. Revance Therapeutics presently has an average rating of “Buy” and an average target price of $32.25.
“Hi, I’m Jeff Brown… I’m about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk’s next big project…
What happens next will shock you…”
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.
Read More: How is the LIBOR rate calculated?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Entertainment Stocks That Are Still Delighting Investors
2020 has created a real-life movie script that many production companies could have only dreamed of. But that dream has been a nightmare for many of the world’s leading entertainment stocks. Movie theaters and live entertainment venues remain shut down. The words “pent-up demand” have never resonated more. Consumers are desperate for ways to be entertained.
That may make it an odd time to consider looking at entertainment stocks. But that would be a mistake. In fact, some entertainment stocks have been among the biggest pandemic winners. This is a trend that is likely to continue as the holidays arrive. The phrase “home for the holidays” is likely to have a new meaning this year. That means consumers will still be looking for ways to be entertained. And now is the time for you to prepare your portfolio for that move.
To be clear, the novel coronavirus was not due to poor management from any company. And you can bet that in the future, many companies will leave some room in their balance sheet for future “acts of God.” But in the meantime, some entertainment stocks have been pandemic winners. And that means they will likely continue to be winners as long as the pandemic lingers.
View the “7 Entertainment Stocks That Are Still Delighting Investors”.
